Characterization of scalp involvement in dermatomyositis based on myositis-specific antibody subsets - 20/11/24
Doi : 10.1016/j.jaad.2024.07.1507
Jagmeet S. Arora, BS, Colin M. Kincaid, BS, Ajay N. Sharma, MD, MBA, Natasha A. Mesinkovska, MD, PhD, Michelle S. Min, MD, MS ⁎ 
Department of Dermatology, University of California Irvine, Irvine, California
∗Correspondence to: Michelle S. Min, MD, MS, Director of Rheumatologic Dermatology, Department of Dermatology, University of California Irvine School of Medicine, 118 Medical Surge I, Irvine, CA 92697Director of Rheumatologic DermatologyDepartment of DermatologyUniversity of California Irvine School of Medicine118 Medical Surge IIrvineCA92697
Key words : alopecia, connective tissue disease, dermatomyositis, myositis-specific antibodies, scalp dermatomyositis, TIF1
| Authors Arora and Kincaid contributed equally as co-first authors. |
|
| Drs Mesinkovska and Min contributed equally as senior co-authors. |
|
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: 2016-3076. |
|
| Previous publication: No data from this study have been previously published. |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 91 - N° 6
P. 1245-1247 - décembre 2024 Retour au numéro
Article précédent
- A study of ultralow dose rituximab as adjuvant to standard of care in treatment of significant and extensive pemphigus vulgaris: A case series
- Nayankumar H. Patel, Jignaben K. Padhiyar, Jahnvi R. Patel, Kathak A. Patel, Megha P. Lakum, Yaksh Pradeep Oza, Harisiddhi Bharatbhai Patel, Prashant Bhikhabhai Chaudhary
- Association between skin-related quality of life and race in patients with moderate-to-severe hidradenitis suppurativa: Analysis of two phase 3 clinical trials
- Bria Midgette, Andrew Strunk, Amit Garg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?